Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Terns Pharmaceuticals $65 million common stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
InSilico Medicine $35 million Series D2 financing
We are advising InSilico Medicine on the financing
Vaccitech $75 million at-the-market offering
The ADSs are listed on the Nasdaq Global Market
RxSight $50 million at-the-market offering
The stock is listed on the Nasdaq Global Market
TransMedics Group $150 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Gilead Sciences $405 million acquisition of MiroBio
We are advising Gilead Sciences on the transaction
Allakos $75 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Taibang Biologic Group $300 million equity raising
We are advising Taibang Biologic Group in connection with its equity raising by a group of investors
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Legend Biotech $403 million follow-on offering
The shares are listed on the Nasdaq Global Select Market